Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis

doi:10.12998/wjcc.v10.i24.8547

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3418)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

152

WORD

HTML

1476

Figures (1-1)

293

Tables (1-5)

523

Sum=2506

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

287

Download

625

Sum=912

Aug 26, 2022 (publication date) through Jan 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Aug 26, 2022; 10(24): 8547-8555
Published online Aug 26, 2022. doi: 10.12998/wjcc.v10.i24.8547

Table 4 Comparison of tumor marker levels between the two groups (mean ± SD)

Index	Research group (n = 44)	Control group (n = 44)	t value	P value
AFU (U/L)
Preoperative	66.41 ± 9.51	68.18 ± 10.84	-0.814	0.418
1 mo after operation	27.04 ± 6.44^a	29.95 ± 8.27^a	-1.842	0.069
AFP (ng/L)
Preoperative	240.8 ± 75.6	228.6 ± 66.3	0.805	0.423
1 mo after operation	78.55 ± 18.04^a	82.01 ± 20.63^a	-0.837	0.405
CEA (μg/L)
Preoperative	18.58 ± 4.20	20.03 ± 4.81	-1.506	0.136
1 mo after operation	3.77 ± 0.89^a	4.01 ± 0.81^a	-1.323	0.189

^aP < 0.05 vs this group before surgery.

AFU: Alpha-L fasosylase; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen.

Citation: Liu D, Fang JM, Chen XQ. Clinical significance of half-hepatic blood flow occlusion technology in patients with hepatocellular carcinoma with cirrhosis. World J Clin Cases 2022; 10(24): 8547-8555
URL: https://www.wjgnet.com/2307-8960/full/v10/i24/8547.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i24.8547